Atea Q2 net loss narrows to $32.9 million; cash falls to $219.5 million
Atea Pharmaceuticals reported a narrower second-quarter net loss of $32.9 million, down from $37.2 million a year earlier, as lower research and development and general and administrative spending more than offset lower interest income. Cash and investments fell from $301.8 million at December 31, 2025 to $219.5 million at June 30, 2026. The release also restates the July C-BEYOND Phase 3 results and gives timing for C-FORWARD topline data and a planned new drug application, which shape the company's path to a possible US launch of BEM/RZR.
Key points
- Net loss of $32.9 million, or $0.41 per share, for the three months ended June 30, 2026, versus $37.2 million, or $0.44 per share, a year earlier.
- Research and development expenses fell to $28.2 million from $32.3 million; general and administrative expenses fell to $7.0 million from $9.1 million.
- Cash, cash equivalents and marketable securities were $219.5 million at June 30, 2026, down from $301.8 million at December 31, 2025.
- C-FORWARD Phase 3 topline results are expected in early first quarter 2027; a new drug application submission is anticipated in the second quarter of 2027.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.